Drug interactions due to efflux transport inhibition at the blood-brain barrier (BBB) have been receiving increasing scrutiny because of the theoretical possibility of adverse central nervous system (CNS) effects identified in preclinical studies. This presentation will review evidence from pharmacokinetic, pharmacodynamic, imaging, pharmacogenetic, and pharmacovigilance studies, along with drug safety reports supporting a low probability of modulating transporters at the human BBB by currently marketed drugs.
Dr. Joseph Polli
Sr. Director & Sr. GSK Fellow
Mechanistic Safety and Drug Disposition
Glaxo Smith Kline
Dr. Polli received his B.Sc. in Molecular and Cellular Biology in 1986 from The Pennsylvania State University, and his Ph.D. in Pharmacology from the Milton S. Hershey Medical Center-The Pennsylvania State University in 1990. From 1990-1993, he was a Pharmacological Research Associate (PRAT) Fellow at the National Institutes of Health. In 1993, he joined GlaxoSmithKline, plc where he is currently a Senior Director and Senior Fellow in the Mechanistic Safety and Disposition Department. His group provides in vitro support for the discovery and registration of clinical drug candidates, which includes mechanistic studies on absorption, distribution, metabolism, elimination, safety and drug interactions. His research interests include membrane transporters that influence drug disposition, application of clinical genetics to drug metabolism/transport, and processes to enhance the development of drug candidates. He has published more than 65 original research papers and was inducted as an AAPS Fellow in 2004. Joe is active in the external scientific community and has made more than 100 invited professional presentations
Organizer: Optivia Biotechnology Inc.
Time: Wed, June 7, 2017 10:00 AM - 11:30 AM PDT
At the courtesy of the speaker, presentation slides are available from Optivia.
Contact Optivia for details.